JP2019038778A - ホウ素含有葉酸誘導体 - Google Patents
ホウ素含有葉酸誘導体 Download PDFInfo
- Publication number
- JP2019038778A JP2019038778A JP2017162387A JP2017162387A JP2019038778A JP 2019038778 A JP2019038778 A JP 2019038778A JP 2017162387 A JP2017162387 A JP 2017162387A JP 2017162387 A JP2017162387 A JP 2017162387A JP 2019038778 A JP2019038778 A JP 2019038778A
- Authority
- JP
- Japan
- Prior art keywords
- boron
- acid derivative
- amino acid
- general formula
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 118
- 150000002224 folic acids Chemical class 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 25
- 150000003862 amino acid derivatives Chemical class 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- 125000005647 linker group Chemical group 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 150000001414 amino alcohols Chemical group 0.000 claims description 8
- 125000004427 diamine group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- 239000012043 crude product Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 101150020457 PBC1 gene Proteins 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 102000006815 folate receptor Human genes 0.000 description 9
- 108020005243 folate receptor Proteins 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- MGEIMAVDBPWSPW-UHFFFAOYSA-N 4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl azide Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N=[N+]=[N-])C=C1 MGEIMAVDBPWSPW-UHFFFAOYSA-N 0.000 description 8
- 101100298996 Arabidopsis thaliana PBC2 gene Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 101000605024 Rattus norvegicus Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 5
- TVBISCWBJBKUDP-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] TVBISCWBJBKUDP-UHFFFAOYSA-N 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001638 boron Chemical class 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001747 pteroyl group Chemical group [H]C1=C([H])C(C(=O)[*])=C([H])C([H])=C1N([H])C([H])([H])C1=C([H])N=C2N([H])C(N([H])[H])=NC(=O)C2=N1 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000036326 tumor accumulation Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- CVZUKWBYQQYBTF-ZDUSSCGKSA-N (4s)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC(O)=O)C(=O)OCC1=CC=CC=C1 CVZUKWBYQQYBTF-ZDUSSCGKSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)下記の一般式(I)
で表されることを特徴とするホウ素含有葉酸誘導体。
で表されることを特徴とするホウ素含有アミノ酸誘導体。
(1)ホウ素含有葉酸誘導体
本発明のホウ素含有葉酸誘導体は、下記の一般式(I)
本発明のホウ素含有アミノ酸誘導体は、下記の一般式(II)
本発明のホウ素中性子捕捉療法用組成物は、上記のホウ素含有葉酸誘導体又はホウ素含有アミノ酸誘導体を含有することを特徴とするものである。
BSHは腫瘍集積性が不十分であることから、現在ホウ素中性子捕捉療法において実質的に使用可能なホウ素薬剤はBPAだけである。このため、現時点では、BPA非感受性がんに対してホウ素中性子捕捉療法を行うことができない。BPAはLAT-1により細胞に取り込まれているが、BPA非感受性がんはこのLAT-1の発現が低下している。本発明のホウ素含有葉酸誘導体は、LAT-1ではなく、葉酸受容体を介して細胞内に取り込まれるので、BPA非感受性のがん細胞に大量に送達することが可能である。
ホウ素中性子捕捉療法では、大量のホウ素薬剤を投与するので、ホウ素薬剤は水に溶け易いことが必要である。本発明のホウ素含有葉酸誘導体は水溶性であり、このような条件を満たしている。
細胞毒性が低いため、副作用などの問題も起き難いと考えられる。
BPAとは異なり、複数のホウ素原子を有しているので、大量のホウ素原子を細胞に送達することが可能である。
<PBC1の合成>
(2)化合物5の合成
(1)化合物8の合成
100Φディッシュ内のHeLa細胞に、EDTA及び1640 RPMI培地(10%FBS及び1%PSを含む)を添加した。HeLa細胞を50mlチューブ中で、1500rpmで3分間遠心分離し、培地を除去し、細胞を1mlあたり50,000細胞になるように希釈した。細胞の希釈には、完全培地を使用した。次に、100μlの細胞(5,000個の細胞)を各ウェルに添加し、一晩インキュベートした。HeLa細胞を、化合物(PBC1、 PBC2、 PBC3、及び PBC4)を溶かした培地で3日間処理した。次に、HeLa細胞に、10μlの5mg/ml MTTを添加し、37℃で2時間インキュベートした。MTTを含むが細胞を含まない1組のウェルについても同様にインキュベートし、コントロールとした。培地を除去した後、100μLのDMSOを各ウェルに加え、620nmのレファレンスフィルターを用いて590nmの吸光度を読み取った。この吸光度から細胞の生存率を求め、IC50を算出した。HeLa細胞の代わりに、U-87細胞及びHCT116細胞を用い、同様にIC50を算出した。結果を表1に示す。
合成したホウ素含有葉酸誘導体に対し、細胞を用いた薬剤の細胞取り込み試験を実施した。用いる細胞は、葉酸受容体が高発現しているMCF-7細胞ならびにHeLa細胞、LAT-1の発現が少なくL-BPA(L-p-ボロノフェニルアラニン)に非感受性のヒト脳腫瘍由来細胞U-87細胞、及び葉酸受容体の発現が少ないA549細胞を使用した。実験条件は、暴露時間を3時間、暴露濃度を100 ppmBで固定し、細胞に薬剤を暴露させた後、ICPにより細胞に取り込まれたホウ素濃度を測定した。また、L-BPAを比較対象に用いた。暴露後はPBSで三回洗浄した後、HClO4/H-2O2=1/2の溶液で70℃, 2 hの条件で灰化を行い、得られた溶液をMilli Q水で5 mLまでメスアップしてICPによりホウ素濃度を測定した。
培地中のPBC1、PBC2、PBC3、PBC4、BSH又はL-BPA(ソルビトール溶液中10%v/w)から各PBC、BSH又はL-BPA溶液(300ppm [B])を調製した。Hela細胞を、1×106細胞/ディッシュの密度で、6ウェルプレート内の培地(1mL)で、5%CO2インキュベーター内で、37℃で24時間培養し、次いで培地を除去し、上記の薬剤溶液で1、3、又は12時間処理した。培地を除去し、細胞を3×PBSで洗浄し、ゴム製器具で集め、60%HClO4と30%H2O2の混合溶媒(1:2 v/v)に70℃で2時間溶解した。疎水性フィルターでろ過した後、得られた溶液のホウ素濃度をICP-OESで測定した。その結果を図3に示した。
細胞試験系において良好な結果が見られたPBC1及びPBC3に対して、マウス大腸がん細胞であるCT26細胞を移植したマウスを用いて臓器別のホウ素濃度を測定した。コントロールには、臨床応用されているL-BPA・フルクトース錯体を用いた。
参考文献1: P. L. Fuchs et al., J. Am. Chem. Soc., 1997, 119, 10003-10014.
参考文献2:V. I. Bregadze et al., Appl. Organometal. Chem. 2007, 21, 98-100.
参考文献3:I. B. Sivaev et al., J. Organometal. Chem., 2008, 693, 519-525.
参考文献4:S. Youland et al., J Neurooncol. 2013, 111, 11-18
Claims (10)
- 下記の一般式(I)
で表されることを特徴とするホウ素含有葉酸誘導体。 - 一般式(I)におけるRが、存在しないか、又はグルタミン酸の残基であることを特徴とする請求項1に記載のホウ素含有葉酸誘導体。
- 一般式(I)におけるXが、クロソドデカボレートから誘導される基であることを特徴とする請求項1又は2に記載のホウ素含有葉酸誘導体。
- 一般式(I)におけるLが、アルキレン基(但し、アルキレン基の1以上の-CH2-は、-O-、-S-、-NH-、又は-CO-で置換されていてもよい。)であることを特徴とする請求項1乃至3のいずれか一項に記載のホウ素含有葉酸誘導体。
- 下記の一般式(II)
で表されることを特徴とするホウ素含有アミノ酸誘導体。 - 一般式(II)におけるRaが、グルタミン酸の残基であることを特徴とする請求項5に記載のホウ素含有アミノ酸誘導体。
- 一般式(II)におけるXが、クロソドデカボレートから誘導される基であることを特徴とする請求項5又は6に記載のホウ素含有アミノ酸誘導体。
- 一般式(II)におけるLが、アルキレン基(但し、アルキレン基の1以上の-CH2-は、-O-、-S-、-NH-、又は-CO-で置換されていてもよい。)であることを特徴とする請求項5乃至7のいずれか一項に記載のホウ素含有アミノ酸誘導体。
- 請求項1乃至8のいずれか一項に記載のホウ素含有葉酸誘導体又はホウ素含有アミノ酸誘導体を含有することを特徴とするホウ素中性子捕捉療法用組成物。
- BPA非感受性がん患者に用いられることを特徴とする請求項9に記載のホウ素中性子捕捉療法用組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017162387A JP7154528B2 (ja) | 2017-08-25 | 2017-08-25 | ホウ素含有葉酸誘導体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017162387A JP7154528B2 (ja) | 2017-08-25 | 2017-08-25 | ホウ素含有葉酸誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019038778A true JP2019038778A (ja) | 2019-03-14 |
JP7154528B2 JP7154528B2 (ja) | 2022-10-18 |
Family
ID=65725413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017162387A Active JP7154528B2 (ja) | 2017-08-25 | 2017-08-25 | ホウ素含有葉酸誘導体 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7154528B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022191262A1 (ja) * | 2021-03-12 | 2022-09-15 | 国立大学法人東京工業大学 | 新規ホウ素薬剤 |
RU2794768C1 (ru) * | 2022-09-07 | 2023-04-24 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | нидо-Карборансодержащие бис-амиды фолиевой кислоты для доставки бора в опухолевые клетки |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009504732A (ja) * | 2005-08-19 | 2009-02-05 | ハマーカップ・アーベー | Bnctに有用なホウ素化合物 |
WO2017026276A1 (ja) * | 2015-08-07 | 2017-02-16 | 国立大学法人東京工業大学 | ホウ素含有化合物とタンパク質とのコンジュゲートを含む医薬組成物 |
-
2017
- 2017-08-25 JP JP2017162387A patent/JP7154528B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009504732A (ja) * | 2005-08-19 | 2009-02-05 | ハマーカップ・アーベー | Bnctに有用なホウ素化合物 |
WO2017026276A1 (ja) * | 2015-08-07 | 2017-02-16 | 国立大学法人東京工業大学 | ホウ素含有化合物とタンパク質とのコンジュゲートを含む医薬組成物 |
Non-Patent Citations (7)
Title |
---|
"葉酸と葉酸レセプターαを利用したドラッグデリバリーシステム", ビタミン, vol. 90巻9号, JPN6022022329, 2016, pages 441 - 444, ISSN: 0004797720 * |
AGARWAL, HITESH K. ET AL.: "Synthesis of closo-1,7-carboranyl alkyl amines", TETRAHEDRON LETTERS, vol. 52(43), JPN6021026606, 2011, pages 5664 - 5667, ISSN: 0004545546 * |
GRUZDEV, D. A. ET AL.: "Synthesis of novel carboranyl derivatives of α-amino acids", RUSSIAN CHEMICAL BULLETIN, vol. 59(1), JPN6021026605, 2010, pages 110 - 115, ISSN: 0004545547 * |
HATTORI, YOSHIHIDE ET AL.: "A novel modification method of peptides and proteins by anionic dodecaborate cage in water", PEPTIDE SCIENCE, vol. 48th, JPN6021026603, 2011, pages 47, ISSN: 0004545549 * |
I.B.SIVAEV ET AL: "Derivatives of the closo-dodecaborate anion and their application in medicine", RUSSIAN CHEMICAL BULLETIN, vol. 51, JPN6021044727, 2002, pages 1362 - 1374, XP002344297, ISSN: 0004797719, DOI: 10.1023/A:1020942418765 * |
NEIRYNCK, P. ET AL.: "Carborane-β-cyclodextrin complexes as a supramolecular connector for bioactive surfaces", JOURNAL OF MATERIALS CHEMISTRY B: MATERIALS FOR BIOLOGY AND MEDICINE, vol. 3(4), JPN6021026602, 2015, pages 539 - 545, ISSN: 0004545550 * |
WU, YE; QUINTANA, WILLIAM: "Coupling of Amino Carboranes to Carboxylic Acid Containing Substrates", INORGANIC CHEMISTRY, vol. 38(9), JPN6021026604, 1999, pages 2025 - 2029, ISSN: 0004545548 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022191262A1 (ja) * | 2021-03-12 | 2022-09-15 | 国立大学法人東京工業大学 | 新規ホウ素薬剤 |
RU2794768C1 (ru) * | 2022-09-07 | 2023-04-24 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | нидо-Карборансодержащие бис-амиды фолиевой кислоты для доставки бора в опухолевые клетки |
Also Published As
Publication number | Publication date |
---|---|
JP7154528B2 (ja) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2624446C9 (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
CA3030907A1 (en) | Chelated psma inhibitors | |
CN111491937A (zh) | 作为精氨酸酶抑制剂的杂环化合物 | |
Zhu et al. | Synthesis and evaluation of new 5-aminolevulinic acid derivatives as prodrugs of protoporphyrin for photodynamic therapy | |
CN114516857A (zh) | Hpk1抑制剂及其用途 | |
JP2022524332A (ja) | ホウ素中性子捕捉療法において使用するためのボリル化されたアミノ酸組成物およびその方法 | |
JP6017766B2 (ja) | 新規な金属サレン錯体化合物の抗がん剤 | |
JP7154528B2 (ja) | ホウ素含有葉酸誘導体 | |
RU2547570C2 (ru) | Лекарственное средство против опухоли головного мозга | |
CN106631957A (zh) | 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用 | |
KR20240045241A (ko) | 붕소 중성자 포획 요법에 사용하기 위한 BTS 및 BTS(OMe)를 포함하는 보릴화 아미노산 조성물 및 그의 방법 | |
JP2006096870A (ja) | ホウ素含有化合物 | |
WO2018112111A1 (en) | Epidermal growth factor receptor (egfr) targeted photosensitizers | |
EA016052B1 (ru) | N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ | |
TWI308569B (en) | Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents | |
JP5806356B2 (ja) | 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 | |
CA3115103A1 (en) | Pi3k inhibitors and uses thereof | |
CN1059896C (zh) | 肿瘤逆转剂组成物及其制备方法 | |
RU2818817C2 (ru) | Борилированные аминокислотные композиции для применения в бор-нейтронозахватной терапии и их способы | |
WO2011147254A1 (zh) | 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用 | |
WO2022191262A1 (ja) | 新規ホウ素薬剤 | |
JP7440914B2 (ja) | ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤 | |
WO2023200671A1 (en) | Tryptamine analogues | |
WO2022037599A9 (zh) | 二氢卟吩衍生物或其可药用盐、其制备方法、用途、及其与超声医疗系统的组合 | |
JP6281901B2 (ja) | 水溶性ポルフィリン誘導体とそれらの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20170831 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200811 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200811 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220719 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220719 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220728 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220809 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220913 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7154528 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |